Image source: Shutterstock

Highlights

  • Contract focuses on pre-clinical development of multi-specific antibody therapy
  • Project expected to conclude within a two-month timeframe
  • Continues long-term collaboration between Physiomics and Numab Therapeutics

Physiomics plc (AIM: PYC), a UK-based data science and mathematical modelling company specialising in healthcare and pharmaceutical research, has announced the signing of a new contract with its established client, Numab Therapeutics AG.

The agreement will see Physiomics applying its expertise in modelling and simulation techniques to support the pre-clinical development of a multi-specific antibody. The experimental therapy aims to stimulate anti-tumor immune responses and is being developed as a potential cancer treatment.

The contract will focus on informing early-stage development strategies by leveraging mathematical models to analyse and predict biological outcomes, contributing to more efficient decision-making in the drug development pipeline.

This project is expected to be completed within the next two months and builds on a series of past collaborations between the two companies. Physiomics and Numab Therapeutics have previously partnered on multiple initiatives involving Model Informed Drug Development (MIDD), particularly in areas requiring advanced simulations to address complex research questions.

While financial details of the agreement have not been disclosed, the announcement reinforces Physiomics’ continued engagement in therapeutic innovation through technical services that aim to enhance understanding of experimental therapies at the pre-clinical level.

Physiomics CEO Dr Peter Sargent commented on the contract, noting the company’s ongoing relationship with Numab and the role of specialist modelling in supporting key development phases.

Physiomics’ approach involves integrating data from pre-clinical studies with predictive modelling tools to help clients optimise drug dosing, scheduling, and response prediction. The company operates in a growing niche that supports pharmaceutical firms looking to reduce development timelines and improve clinical outcomes through data-driven decision-making.

The partnership with Numab Therapeutics highlights ongoing industry reliance on computational modelling as part of broader strategies to de-risk drug development, particularly in complex therapeutic areas like oncology.